Wilmington-area pharma start-up NiKang secures $200 million in financing

0
Reading Time: < 1 minute

Delaware-based NiKang Therapeutics Inc. completed an oversubscribed $200 million series C financing.

Last year, the company received $50 million in series B financing.

“We are thrilled to have such an outstanding group of investors as our shareholders” said Zhenhai Gao, CEO of NiKang. “Their support of our vision allows us to build the world’s leading precision oncology company. We are now well positioned to rapidly advance our pipeline into clinic including our differentiated HIF-2 alpha inhibitor, and to bring our company to the next level of growth.”

“This financing is a testament to the quality of our science and team,” Kelsey Chen, chief finance officer, stated. “Since joining NiKang, I have witnessed the passion and dedication by a group of talented scientists who are devoting their lives to advancing treatments for patients. We are grateful to be recognized by such a high caliber group of investors.”

“This financing is a testament to the quality of our science and team,” Kelsey Chen, Ph.D., MBA, chief finance officer, added. “Since joining NiKang, I have witnessed the passion and dedication by a group of talented scientists who are devoting their lives to advancing treatments for patients. We are grateful to be recognized by such a high caliber group of investors.”

Proceeds will be used to advance the company’s lead drug candidates into the clinic, expand the pipeline and fund internal drug discovery programs.

NiKang Therapeutics, located in the Delaware Innovation Space near Wilmington, is a clinical stage biotech company focused on discovering and developing innovative small molecules cancer medicines to help patients with unmet medical needs.

The Innovation Space is a venture that provides lab and other space for start-up companies.

For more information, visit http://nikangtx.com

Facebook Comments